Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centogene AG - |
RCV001251137 | SCV001426637 | likely pathogenic | Cortical dysplasia-focal epilepsy syndrome | criteria provided, single submitter | clinical testing | ||
Gene |
RCV002466651 | SCV002762360 | likely pathogenic | not provided | 2022-06-07 | criteria provided, single submitter | clinical testing | Reported previously as a likely pathogenic variant in the heterozygous state in a patient with micrognathia, hypertelorism, intellectual disability, and seizures. A second likely pathogenic heterozygous variant was also reported; however, phase was unknown (Bertoli-Avella et al., 2021); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 32860008) |